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ICUAbstract The proﬁle of an ideal volume substitution solution can be deﬁned by volume effect and
safety. The volume effect should be stable and reliable, offer a constant plateau effect and be easily
controllable. Many in depth characteristics has been offered by recognized societies [1] and includes:
no tissue storage, no plasma accumulation, no inﬂuence on haemostasis, no inﬂuence on the immune
system, no infectivity, no antigenicity, no allergenic potential, no proinﬂammatory properties, no
toxicity, teratogenity or mutagenity, no inﬂuence on diagnostic tests, good compatibility with other
medication, good tolerance, and complete elimination. Research has shown that it is possible to meet
these objectives in the development of hydroxyethyl starches (HES) by optimizing the combination
of concentration, the molecular weight, the degree and pattern of substitution. A new starch (HES
130/0.4) has therefore been developed. This new generation of HES offers the same volume effect and
duration as the previous standard HES 200/0.5, yet with more favorable pharmacological character-
istics and an improved safety proﬁle. The following article is a collection of experts’ opinion
from different recognized universities, hospitals and healthcare organizations about the evidence
based clinical decisions when using Waxy-Maize HES 130/0.4 (Voluven) in various clinical
situations.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.Contents
1. When should an anesthetist consider Waxy-Maize HES 130/0.4 usage and why? . . . . . . . . . . . . . . . . . . . . . . . . . . 198
2. When should an intensivist consider Waxy-Maize HES 130/0.4 usage and why?. . . . . . . . . . . . . . . . . . . . . . . . . . . 198
3. What are the other beneﬁts for Waxy-Maize HES 130/0.4 usage rather than being a plasma expander? . . . . . . . . . . 199
4. What are the advantages that Waxy-Maize HES 130/0.4 brings to clinical practice over older starches? . . . . . . . . . . 199
5. What should be the consensus of Waxy-Maize HES 130/0.4 usage in comparison to albumin and crystalloids? . . . . 199
6. Among starches used in ﬂuid therapy regimens, why Waxy-Maize HES 130/0.4 considered a class of its own? . . . . . 199
7. Why should we consider Waxy-Maize HES 130/0.4 for a critically ill patient although there are some reports indicating
increased risk of acute renal injuries in septic patients when using older starches? . . . . . . . . . . . . . . . . . . . . . . . . . 199
8. What is the role of Waxy-Maize HES 130/0.4 in guarding against intra abdominal hypertension and what is the expected
beneﬁt in the ICU setting? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
9. According to the American practice, crystalloids should be the right choice in septic patients in the ICU, why should we
consider Waxy-Maize HES 130/0.4 for these patients? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
10. There are some publications referring to Waxy-Maize HES 130/0.4 as the right choice for routine preloading before spinal
anesthesia while there are some other publications doubting the principle of pre-lauding itself. What do you think is the
beneﬁt of using Waxy-Maize HES 130/0.4 in such cases and is it justiﬁed to consider Waxy-Maize HES 130/0.4 as the right
choice ﬂuid? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
11. What is the current clinical experience of Waxy-Maize HES 130/0.4 in pediatric surgery? . . . . . . . . . . . . . . . . . . . 200
12. What are the major beneﬁts of Waxy-Maize HES 130/0.4 usage in cardiac surgery? . . . . . . . . . . . . . . . . . . . . . . . 200
13. Can Waxy-Maize HES 130/0.4 be considered in burn patients? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
14. Is it safe to use Waxy-Maize HES 130/0.4 in transplant surgery? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
15. Why is Waxy-Maize HES 130/0.4 better than potato starches even if tetra starch? Does the type of raw material make that
difference?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
16. What is the incidence of anaphylactoid reactions with Waxy-Maize HES 130/0.4? . . . . . . . . . . . . . . . . . . . . . . . . . 200
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2001. When should an anesthetist consider Waxy-Maize HES 130/
0.4 usage and why?
Waxy-Maize HES 130/0.4 should be considered for prophy-
laxis and treatment of hypovolaemic cases being effective plas-
ma volume expander giving 100% volume expansion and with
4–6 plateau effect [2] compared to crystalloids which deliver
only 20–30% volume expansion with 30 min duration of
expansion. Along with being effective, Waxy-Maize HES
130/0.4 has an excellent safety proﬁle at high dose application
reaching 50 mg/kg bw/day in all age groups including children
[3–8]. Its safety has been proved also in repeated administra-tion [7], and with a highly recognized amount of evidence
based literature that reached more than 180 publications along
with proven safety records in more than 30 million patients.
2. When should an intensivist consider Waxy-Maize HES 130/
0.4 usage and why?
In addition to the previous points, Waxy-Maize HES 130/0.4
would help in reaching an optimized tissue oxygenation and
improved microcirculation when compared to crystalloids as
established in Lomivorotov [9] and Dubin [10]. Waxy-Maize
HES 130/0.4 also helps in reducing inﬂammatory response
Waxy-Maize HES 130/0.4; evidence based clinical decisions 199and endothelial activation along with the recognized charac-
teristic of the capillary ceiling properties of Waxy-Maize
HES 130/0.4 in cases of capillary leakage syndrome with
comparison to different ﬂuid regimens [11–21] among which
is albumin which appeared to be inferior to Waxy-Maize
HES 130/0.4 which reduced incidence of pulmonary oedema
and improved of the APACHE II score as established by Pal-
umbo [22]. The clear advantage in reduced total ﬂuid admin-
istration when using Waxy-Maize HES 130/0.4 also helps in
guarding against intra-abdominal hypertension with compar-
ison to crystalloids as in Vidal [23].3. What are the other beneﬁts for Waxy-Maize HES 130/0.4
usage rather than being a plasma expander?
Waxy-Maize HES 130/0.4 can assist clinician in achieving
better tissue oxygenation than crystalloids through improve-
ment of microcirculation while reducing the total ﬂuid
administration [9,10,24]. Another beneﬁt is the lower inﬂam-
matory response with Waxy-Maize HES 130/0.4 in compari-
son to crystalloids and albumin by lowering the inﬂammatory
response and endothelial activation [11–21]. The improve-
ment of pulmonary functions in comparison to albumin has
been established in favor of Waxy-Maize HES 130/0.4 in sep-
tic patients [22].4. What are the advantages that Waxy-Maize HES 130/0.4
brings to clinical practice over older starches?
With Waxy-Maize HES 130/0.4, there is no plasma accumula-
tion even in repetitive high doses as established by Waitzinger
[25] and Ellger [5]. Waxy-Maize HES 130/0.4 has very minimal
effect on blood coagulation and many evidence based assess-
ment established that with Waxy-Maize HES 130/0.4 there is
less blood loss in comparison to Pentastarch which was re-
viewed by Kozek-Langenecker [26]. Waxy-Maize HES 130/
0.4 has a better renal proﬁle even in severe renal impairment
even at creatinine clearance close to 15 ml/min as established
by Jungheinrich [27]. Waxy-Maize HES 130/0.4 has a maximal
daily dose of 50 ml/kg bw/day which is by far higher than older
starches such as Hetastarch (20 ml/kg bw/day) and Pentastarch
(33 ml/kg bw/day). The FDA has approved Waxy-Maize HES
130/0.4 in treatment and prophylaxis of hypovolaemia in
adults, pediatrics and neonates in December 2007 [28].5. What should be the consensus of Waxy-Maize HES 130/0.4
usage in comparison to albumin and crystalloids?
Albumin has been a choice for treatment of hypovolaemia in
critically ill patients until the 1998 Cochran review [29]
showed increased mortality when compared to isotonic saline.
Then the SAFE study [30] showed that both have the same
mortality rates in the ICU settings. Waxy-Maize HES 130/
0.4 has capillary sealing properties with less possibility of pul-
monary edema than albumin as established by Palumbo [22].
When taking into consideration the high cost of albumin
products, Waxy-Maize HES 130/0.4 appears to be more
cost-effective than albumin. Another advantage is that
Waxy-Maize HES 130/0.4 has a quicker infusion rate than
albumin (25 ml/min vs. 5 ml/min) [31]. The availability ofWaxy-Maize HES 130/0.4 is better than albumin solutions
which have been proved through history of shortage of albu-
min supply due to donors’ restrictions. The handling of albu-
min solution is requiring special storage care to avoid
alteration of the protein nature of the solution while HES
products do not require such restrictions.
In comparison with crystalloids Waxy-Maize HES 130/0.4
has a volume expansion of 100% while crystalloids have only
20–30% effect. The plateau effect of Waxy-Maize HES 130/
0.4 with duration of 6 h is more clinically favorable in com-
parison to crystalloids which have duration of expansion that
lasts only 30 min even with hypertonic saline. Waxy-Maize
HES 130/0.4 maintains hemodynamics with less volume than
crystalloids lowering the morbidity associated with excess vol-
ume and with its rheological properties it improves microcir-
culation and tissue oxygenation resulting in better organ
function, while crystalloids worsen it [9,10]. Waxy-Maize
HES 130/0.4 reduces inﬂammatory response and capillary
leakage resulting in less edema than different ﬂuid regimens
[11–22].
Waxy-Maize HES 130/0.4 is more effective than crystal-
loids in reducing the incidence of hypotension if used as pre-
loading ﬂuid before spinal anesthesia as established by Sucre
[32], Ko [33], Barbe [34], Madi-Jebara [35], and Siddik [36].6. Among starches used in ﬂuid therapy regimens, why Waxy-
Maize HES 130/0.4 considered a class of its own?
Waxy-Maize HES 130/0.4 holds the best evidence based med-
icine among all starches: 10 years of clinical experience, 180
publications, and more than 30 million patients’ usage.7. Why should we consider Waxy-Maize HES 130/0.4 for a
critically ill patient although there are some reports indicating
increased risk of acute renal injuries in septic patients when using
older starches?
Safety of Waxy-Maize HES 130/0.4 on renal functions has
been proved in a lot of critically ill patients in more than 20
clinical trials [7,8,27,37–47].
The report of increased AKI is associated with the use of
older starches such as Pentastarch 10% (hyperoncotic) and is
mostly related to its accumulation [48]. While Waxy-Maize
HES 130/0.4 proved to have no accumulation even with renal
impairment: with comparison to older starches as in Junghein-
rich [27]. Clinicians should always look for the right HES:
Waxy-Maize 130/0.4 with reduced molecular weight and re-
duced molar substitution.8. What is the role of Waxy-Maize HES 130/0.4 in guarding
against intra abdominal hypertension and what is the expected
beneﬁt in the ICU setting?
Waxy-Maize HES 130/0.4 reduces total administration of
resuscitating ﬂuids (reduce positive ﬂuid balance). A high
amount of resuscitating ﬂuids is the major risk factor for in-
creased IAH as established by Vidal [23]. In the ICU as re-
ferred by Malbrain [49], patients with IAH (>12 mm) leads
to a mortality rate of 38.8% while patients with no IAH had
mortality rates of 22.2%.
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right choice in septic patients in the ICU, why should we consider
Waxy-Maize HES 130/0.4 for these patients?
There is no contra-indication of using Waxy-Maize HES 130/
0.4 (as a colloid) in any American guidelines. United States
experience with Waxy-Maize HES 130/0.4 started very
recently: Waxy-Maize HES 130/0.4 FDA approval was in
December 2007 [28] while the actual usage started late 2008.
There is an increased interest in using Waxy-Maize HES
130/0.4 in the states nowadays with matching reports of its
safety and efﬁcacy to the worldwide experience that started
more than 10 years ago when Waxy-Maize HES 130/0.4 was
launched in Europe. Voluven’s advantages in septic patients
includes: capillary ceiling properties in capillary leakage syn-
drome [11–21] reduction of the total ﬂuid administration which
will guard against IAH in comparison to crystalloids [23], re-
duced incidence and severity of oedema [22].
10. There are some publications referring to Waxy-Maize HES
130/0.4 as the right choice for routine preloading before spinal
anesthesia while there are some other publications doubting the
principle of pre-lauding itself. What do you think is the beneﬁt of
using Waxy-Maize HES 130/0.4 in such cases and is it justiﬁed
to consider Waxy-Maize HES 130/0.4 as the right choice ﬂuid?
There are about 6 clinical trials showing that Waxy-Maize HES
130/0.4 ismore efﬁcient compared to crystalloids toprevent hypo-
tension after spinal anesthesia during C-Section [32–36]. And
there is an ongoing trial named theCAESAR trial also evaluating
Waxy-Maize HES 130/0.4 in such cases [50]. The debate of pre-
laude or not is yet not conclusive, but there is a pile of evidence
supports the prevention of hypotension induced by Spinal Anes-
thesiawhenpre-laudingwithWaxy-MaizeHES130/0.4 especially
that you use half (or even one-third) the amount of crystalloids.
Waxy-Maize HES 130/0.4 was referenced as ‘‘The right choice
for routine Preloading before spinal anesthesia’’ [33].
11. What is the current clinical experience of Waxy-Maize HES
130/0.4 in pediatric surgery?
Seven published clinical trials studying Waxy-Maize HES 130/
0.4 in pediatrics up to 50 ml/kg/day including cardiac surgery
and compared to albumin [6,51–56].12. What are the major beneﬁts of Waxy-Maize HES 130/0.4
usage in cardiac surgery?
Beneﬁts in cardiac surgery includingusingWaxy-MaizeHES130/
0.4 as priming solutionwith comparison to crystalloids and albu-
min has been established by many authors such as Hengo [57]:
 Well characterized plasma volume expansion.
 Large volume (50 ml/kg bw/ day).
 Minor effects on haemostasis.
 Minor inﬂuence on renal function.
 Relative rapid elimination.
 Reduction of endothelial cell activation and inﬂammatory
response.
 Minimal risk of anaphylactic reactions.13. Can Waxy-Maize HES 130/0.4 be considered in burn
patients?
In Sudhakar [58] ‘‘Waxy-Maize HES 130/0.4 vs. Ringer’s Lac-
tate’’, and in Shen [59] results indicate that the optimum qual-
ity of circulating blood replenishment and elimination of
hypovolaemia are obtained by the use of hydroxyethyl starch
130/0.4 that offers advantages as the rate of blood concentra-
tions and maintenance of volume levels as well as increasing
oxygen delivery, resulting in quicker recovery from shock
and improvement of burn wound trophism.14. Is it safe to use Waxy-Maize HES 130/0.4 in transplant
surgery?
Waxy-Maize HES 130/0.4 has been used in two Kidney trans-
plant trials (Blasco [40], Pavlidis [45]) and one liver transplant
trial (Mukhtar [8]) vs. albumin and it was recommended for
routine use.
15. Why is Waxy-Maize HES 130/0.4 better than potato
starches even if tetra starch? Does the type of raw material make
that difference?
The superiority of Waxy-Maize HES 130/0.4 is obtained from:
– Differences in raw materials.
– Differences in molecular weight, molar substitution and
substitution pattern.
– Differences in amylose content and degree of branching
(higher amylose/lower branching in potato-starches)
[60,61].
– Difference of phosphate content (higher in potato-starches)
[62].
– Incidence of hyperbilirubinemia with potato-starches [63].
– Higher number of evidence based literatures in comparison
to potato starches which are:
– Very few (mostly in vitro studies).
– Not comparing safety with colloids such as Waxy-Maize
HES 130/0.4 in clinical settings.
16. What is the incidence of anaphylactoid reactions with Waxy-
Maize HES 130/0.4?
Of all colloids, hydroxyethyl starch has the lowest rate of aller-
gic reactions documented (approx. 0.06%). Major Anaphylac-
toid reactions (Grade III and IV) are very rare during HES
therapy (Ring and Meßmer, 1977; Laxenaire et al., 1994;
Dieterich et al. 1998) [64].
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